In addition, we found reduced phosphorylation of the PP2A targets AKT and ERK after FTY720 treatment and, interestingly, we validated these results in a large series of early breast cancer patients, observing a significant correlation between PP2A phosphorylation/inhibition through the CPscore and AKT and ERK phosphorylation levels. This evidence concerns the gene AKT1 and breast cancer.